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Abstract. – This review illustrates some brief 
considerations of the medical use of cannabis re-
cently issued in Italy. History and uses of canna-
bis throughout centuries and different countries 
are illustrated together with a description of bota-
ny and active phytocannabinoids. Then, medical 
use of cannabis anti-pain treatment for patients 
resistant to conventional therapies is described 
in case of chronic neuropathic pain, spasticity, 
for anticinetosic and antiemetic effect in nausea 
and vomiting caused by chemotherapy, for appe-
tite stimulating effect in cachexia, anorexia, loss 
of appetite in cancer patients or patients with 
AIDS and in anorexia nervosa, hypotensive effect 
in glaucoma resistant to conventional therapies 
and for reduction of involuntary body and facial 
movements in Gilles de la Tourette syndrome. 
Italian most recent legislation on medical can-
nabis is detailed with some law proposals, also 
showing the inconsistent legislation within Euro-
pean Union. Some final considerations of future 
studies are also reported.
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Introduction
In the current health context, health is meant 
in the largest sense of the term, as a condition of 
physical and psychological well-being. Even the 
code of medical deontology, in its last version of 
2014 1, considers the well-being of the patient as 
a priority obligation for the physician. Also the 
society operates in this direction. An important 
example is that referred to the well-known events 
of the biological testament, that of medically as-
sisted procreation with related problems 2,3 and 
finally the issue of transplants. Indeed, the last 
years experimentation in the field of transplants 
are aimed not only to save lives, but also to im-
prove the patients quality of life. A classic exam-
ple is the transplantation of the hand and that of 
uterus4.
However, the global economic crisis has obli-
ged the prevalence of management and organi-
zational aspects, the implementation of some 
investigations at the expenses of others, affected 
by economic reasons, lack of resources and fun-
ding. More and more often, the autonomy of the 
professional in detecting the most appropriate for 
a patient has to be faced not only with financial 
constraints, but also with indications, recommen-
dations or guidelines. These latter are issued at 
various levels by public bodies with the aim of 
observing predetermined financial constraints. 
In this perspective, with a reduction in costs or 
a simple resources rationalization, the goal of 
achieving the well-being of the patient risks to be 
hardly feasible.
Treatment of Pain and its Variables
In the medical experience, pain represents one 
of the most important manifestations of the dise-
ase. Moreover, it has to be said that, among the 
symptoms, it is the one that mostly compromises 
the quality of life. Inappropriate management of 
pain creates very important physical, psycholo-
gical and social consequences, especially in the 
most debilitating forms of pain - such as chronic 
ones - in which patient assistance is a real emer-
gency for the Italian health system. Even the Code 
of Medical Deontology, in the Article 3, clarifies 
that among the duties of the physician or medi-
cal surgeon there is “the treatment of pain and the 
relief from suffering”5. The evolution of the con-
cept of palliative care is found in the terminology 
currently used: in the new Code “the relief from 
suffering” is replaced by “pain therapy” (Article 
39). The expression “pain therapy” underlies an 
important concept: pain has to be measured and 
treated not at the discretion of the physician (doc-
tor), but on the basis of knowledge and protocols 
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that allow to quantify and effectively treat it.
Therefore, by excluding disproportionate the-
rapies and protecting the dignity of the person 
who has be assured on the resolution of pain, the 
treatments - as far as possible - have to be sui-
table in preserving the quality of life. Indeed, the 
“quality of life” corresponds to a certain degree 
of psycho-physical autonomy, cognitive qualities, 
residual work capacity, ability to recover relations 
with society, with the family and with the wor-
ld of work that can qualify a life as qualitatively 
acceptable. Therefore, in addition to the doctor 
(physician) duty, adequate pain therapy has to be 
considered a right of the patient, which has to be 
accompanied, through multidisciplinary approa-
ches, in the difficult path of a disease characteri-
zed by the presence of pain.
Cannabis: history and Uses of a 
Much-Discussed Plant
Cannabis, also known as marijuana, ganja, pot, 
kif, hemp, is one of the oldest psychoactive plan-
ts known to mankind. It is native to the regions 
of Central Asia, but is spread all over the world. 
It is believed that the name derives from the As-
syrian “qunnubu” or” qunnabu”6. The most an-
cient human artifact, a piece of hemp fabric, was 
discovered in Mesopotamia and dates back to the 
8th century BC. Numerous ancient writings dealt 
with the pharmacological and psychoactive pro-
perties of cannabis. In the 1st century AC, Plinius 
the elder described in his “Natural Stories” that a 
decoction of the cannabis root could be used to al-
leviate the stiffness of the joints, gout and related 
conditions7. The medical use of cannabis comes 
from the ancient times: in this regard there is do-
cumentation in Chinese medical texts dating back 
to 2800 BC, where its consumption is indicated 
the intake for a wide range of diseases8. In Europe, 
the spread Cannabis dates back to the 19th century, 
on the occasion of Napoleon’s military campaigns 
in Egypt. The first scientific studies date back to 
1839: O’Shaughnessy, an Irish doctor, administe-
red cannabis to patients suffering from various 
diseases, from epilepsy to rheumatism, finding 
an anticonvulsant, analgesic, antiemetic efficacy. 
During the 19th and the early years of 20th century, 
cannabis was a medical product commonly used 
in clinical practice. Its success, as an active phar-
macological compound, also arrived to America. 
Nevertheless, at the beginning of the 20th century 
more effective treatments came into force: vacci-
nes against cholera and tetanus, antibiotics for go-
norrhea, which prevented or treated the cause of 
the disease instead of its symptoms, psychotropic 
drugs such as barbiturates, which replaced can-
nabis in the psychiatric area. Furthermore, in the 
treatment of pain, acetylsalicylic acid and more 
generally analgesics, started to be more effecti-
vely used9. In any case, the cause of the decline in 
the pharmacological use of cannabis was its phar-
macological instability whereby the plant effects 
were difficult to predict and standardize. The acti-
ve principle delta-9-tetrahydrocannabinol (THC) 
had not yet been isolated and the effects of the 
galenic preparations, in terms of pharmacologi-
cal potency, were closely related to the concentra-
tion of this compound. Many variables influenced 
its concentration: e.g. the origin of the plant, its 
freshness, as well as its storage. Furthermore, to 
limit its use, there was also a factor of an econo-
mic nature. Indeed, the importation of hemp had 
becoming increasingly difficult and expensive in 
relation to the conflicts with India and, more ge-
nerally, to the two world conflicts.
As a result, the use of cannabis for therapeu-
tic purposes was increasingly limited up to the 
prohibition of its use with the Single Convention 
on Narcotic Drugs of 196110. Only several decades 
later, at the beginning of the 21st century, cannabis 
has been readmitted as a pharmacological active 
drug and “medical cannabis” used and legalized 
for therapeutic purposes in many countries.
Botany and Active Ingredients
According to the official modern taxonomy, 
cannabis belongs to the Cannabaceae family, to-
gether with hop. It is a dioecious plant (there are 
separate male and female plants) and the female 
flowering tops are the ones to produce the largest 
amount of the resinous substance containing the 
psychoactive ingredient, THC. There are more 
than 460 chemical components of the plant, and 
more than 60 presenting the typical structure of 
cannabinoids. Among these, THC, presents at 
about 1.5% total flowering tops weight, is the only 
one with psychoactive properties. Research on its 
potential use in the medical field has recognized 
it as the main responsible for the pharmacological 
properties of the plant, although other compounds 
contribute to some of these effects. In particular 
cannabidiol, without psychoactive effects, but 
with antipsychotic, analgesic and anti-inflam-
matory ones. When THC is given together with 
CBD, there is a reduction in anxiety, dysphoric 
and potential effects on the memory. The pharma-
cokinetic properties of cannabis vary depending 
on the administered dose and route of administra-
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tion. In his discretion, the doctor decides the route 
of administration and the doses to be used taking 
into account the therapeutic needs of the patient. 
The doctor should discuss with patients the po-
tential benefits and risks of cannabis since the 
decision to prescribe and use cannabis prepara-
tions have to be shared with the patient, who must 
give written informed consent. Again, the doctor 
has to inform the patient of the main drawbacks, 
underlining that the use of cannabis may lead to 
positivity to Antidrug tests (Decree 309/90), dop-
ing tests (Law 376/2000)11,12 tests indicated in the 
Highway Code (Article 187 of the Highway Code: 
Guide in state of psycho-physical alteration due 
to the use of drugs). The patient should inform the 
doctor if he/she is taking any other medication, 
so that the doctor can evaluate the possible drug 
interactions before prescribing cannabis-based 
preparations.
Medical Use of Cannabis
The use of compounds with therapeutic activity 
has to comply with quality and safety standards. 
These standards are guaranteed by scientific stud-
ies and scrupulous monitoring of the drug used in 
the experiments. Let’s start from the available sci-
entific data we have. Recently, controlled and ob-
servational clinical studies have been conducted 
and systematic and meta-analysis of international 
indexed literature have been reported to evaluate 
cannabis therapeutic effects 13. The majority of 
the controlled studies have been carried on syn-
thetic cannabinoids (dronabinol, nabilone, levon-
antradol, not available in Italy) or nabiximols (an 
oromucosal spray with specific THC and CBD 
dosage available in Italy). Only two studies used 
smoked or vaporized marijuana, five studies used 
smoked THC, seven oral preparations of THC. 
Synthetically, the results were the following:
• Nauseas and vomiting following chemothera-
py (37 reports - 1772 participants). In 14 studies 
nabilone was used, in 6 ones THC in capsules, 
in 4 ones levonantradol, in 3 ones dronabinol, 
in 1 nabiximols. In all these studies cannabi-
noids resulted to be effective 14.
• Stimulation of appetite in HIV patients (4 re-
ports - 255 participants). All studies involved 
dronabinol and the effect of marijuana smoke 
or dronabinol intake compared with placebo 
was studied: weight gain was demonstrated in 
both types of administration15.
• Chronic pain (28 reports - 2454 participan-
ts). 13 studies involved nabiximols, 4 smoked 
THC, 5 nabilone, 3 oromucosal THC sprays, 
1 vaporized cannabis, 1 ajulemic acid and 1 
THC oral. A study compared nabilone with 
amitriptyline, all the others compared acti-
ve compound with placebo. The treated pain 
had different origins: neuropathic pain, tumor 
pain, diabetic neuropathy, fibromyalgia, HIV 
neuropathy, multiple sclerosis, and rheumatoid 
arthritis. The patients enrolled were treated 
with cannabinoids and the pain symptomato-
logy improved in all cases16.
• Spasticity caused by multiple sclerosis or pa-
raplegia (33 reports - 2280 patients). 6 studies 
involved nabiximols, 4 THC/CBD (2 together 
with dronabinol), 3 dronabinol, 1 nabilone, 
1 ECP002A and 1 THC. Cannabinoids, in 
all their formulations and without significant 
differences between them, provided improve-
ments in spasticity.
• Anxiety disorders. The data came from some 
studies whose primary outcome was chronic 
pain. In any case they showed a decrease in 
anxiety17.
• Sleep disorders (5 studies - 54 participan-
ts). All the studies involved nabilone, which 
has been shown to improve the sleep apnea/
hypopnea index. In other studies with diffe-
rent primary outcome, the quality of sleep was 
assessed, with improvement reported for all 
cannabinoid formulations (best outcomes for 
nabiximols)18.
• Glaucoma (6 participants). No differences 
between placebo and cannabinoids treatment19.
• Tourette syndrome (2 studies - 36 participan-
ts). Improvement in the severity of tics in pa-
tients taking THC in capsules when compared 
to placebo20.
Severe adverse events were more frequent in 
cannabinoid-treated populations than in controls. 
To date, no data on long-term adverse events of 
cannabinoids used for medical purposes are avai-
lable.
Taken together, the presented data show a mo-
derate efficacy of cannabinoids in chronic pain 
and spasticity, a lower efficacy in all other indi-
cations.
Other possibilities of medical use of cannabis 
with minor importance have been reported in the 
literature and, among these, there are antitumor 
effects21. 
Nevertheless, from an epidemiological point 
of view, the treatment of chronic pain is an indi-
cation that has the greatest impact on population 
therapeutic needs and, consequently, on cannabis 
production. Recent studies22-24 report that 45-80% 
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of patients using cannabis-based products use 
them for pain management. As for all the other 
drugs, cannabis provides side effects25,26.
Italian Legislation on Medical Cannabis 
and Cannabinoids
In Italy, doctors have been able to prescribe 
cannabis products and synthetic cannabinoids for 
therapeutic use since 1998, with a non-repeatable 
prescription. The Ministerial Decree of 18 April 
200727 include natural and synthetic cannabinoid 
derivatives in the Table of substances with thera-
peutic activity, correcting a coarse error of Law 
49/2006 (so-called Fini-Giovanardi) that placed 
these substances among those lacking of this acti-
vity. It is, therefore, possible at moment to prescri-
be such products. Since 2007, Italy has recognized 
the therapeutic use of THC, the active ingredient 
of cannabis, and of two other similar substances 
of synthetic origin, dronabinol and nabilone.
Subsequently, with the Ministerial Decree da-
ted 23rd January 201328, the Ministry of Health 
included in the B section of the Medicinal Table 
active compounds of cannabis plant origin: com-
pounds and preparations, including extracts and 
dyes. The doctor can, therefore, prescribe can-
nabis products for therapeutic purposes and any 
pharmacy, if properly supplied, can distribute 
cannabis products in the form and dose as pre-
scribed by the doctor.
Furthermore, according to the cooperation agre-
ement between the Ministry of Health and the Mi-
nistry of Defense of 18 September 2014, Italy star-
ted the production of national cannabis, previously 
imported from Dutch crops through the Office of 
Medicinal Cannabis. Indeed, starting from Decem-
ber 14, 2016, cannabis-based FM2 product, produ-
ced by Military Pharmaceutical Chemical Works 
of Florence, Italy in agreement to the Good Manu-
facturing Practices (GMP) of the European Union, 
is available to be prescribed. FM2 cannabis consi-
sts of unfertilized, dried and milled female inflo-
rescences containing 5-8% tetrahydrocannabinol 
(THC) and one of cannabidiol (CBD) of 7.5-12% 
29,30. There are also cannabigerol, cannabicromhe-
ne and tetrahydrocannabivarin in percentage <1%. 
FM2 cannabis, grown in Good Agricultural and 
Collecting Practices (GACP) and produced accor-
ding to GMP, is manufactured in accordance with 
the European Union directives on active substan-
ces for the production of medicines. The technical 
documentation of the product is registered at the 
Italian Drug Agency.
Following the coming into force of the Mini-
sterial Decree of 9 November 201531, the General 
Directorate of Medical Devices and the Pharma-
ceutical Service of the Ministry of Health issued a 
circular with all the information that doctors and 
pharmacists have to follow for the use of FM2 
cannabis for therapeutic purposes: prescription 
Table I. Indications for medical cannabis (as reported in the Official Gazette n. 279 from 30-11-2015).
• Analgesia in diseases involving spasticity associated with pain (multiple sclerosis, spinal cord injury) resistant to 
conventional therapies.
• Analgesia in chronic pain (with particular reference to neurogenic pain) in which treatment with non-steroidal anti-
inflammatory drugs or with cortisone or opioid drugs has proved to be ineffective.
• Anticinetosic and antiemetic effect in nausea and vomiting, caused by chemotherapy, radiotherapy, HIV therapies, which 
cannot be obtained with traditional treatments.
• Appetite stimulating effect in cachexia, anorexia, loss of appetite in cancer patients or patients with AIDS and in anorexia 
nervosa, which cannot be obtained with standard treatments.
• Hypotensive effect in glaucoma resistant to conventional therapies.
• Reduction of involuntary body and facial movements in Gilles de la Tourette syndrome, which cannot be achieved with 
standard treatments.
Table II. Side effects of medical cannabis.
Tachycardia
Hypotension
Paranoia
Dizziness
Reduction of cognitive development and psychomotor performance, alteration of attention and memory
Psychiatric disorders
Damage to the airways and lungs
Risk of addiction weight reduction at newborn birth if used during pregnancy
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and gender without indication of the identity of 
patients (D. L. 30 June 2003, No. 196) (Article 
4). Each year, the regions have to communicate, 
by 31 May, to the Cannabis State Organization, 
the amount of cannabis-based active substan-
ce they need for the following year. If further 
amount of cannabis are needed beyond those 
cultivated by Military Pharmaceutical Chemi-
cal Works of Florence, Italy, by decree of the 
Minister of Health, one or more companies 
can be identified, and authorized for cannabis 
cultivation as well as for processing by “Good 
agricultural and collecting practices” (GACP), 
in accordance the President of the Republic De-
cree of 9 October 1990, n. 309,
Article 4. In order to facilitate the use of can-
nabis-based preparation, Military Pharmaceutical 
Chemical Works provide for the development of 
new preparations for subsequent distribution to 
pharmacies, which dispense them on the basis of 
a non-repeatable medical prescription. 
Article 7 (Information campaigns). The Mi-
nistry of Health, as Cannabis State Organiza-
tion, publishes on its institutional website the 
contributions that are sent every six months by 
the Italian Drug Agency and the National Insti-
tute of Health on the state of scientific evidence 
on the medical use of cannabis, aimed at pro-
moting knowledge and disseminating informa-
tion to physicians and pharmacists on the use of 
cannabis-based products.
Article 8 (Training of medical, health and 
social care personnel). Following to article 8, 
paragraph 2, of Law March 15, 2010, n. 38, a 
periodic updating of medical, health and social 
care staff is organized and achieved through 
the attainment of training credits. These latter 
are intended to acquire specific professional 
knowledge on the therapeutic potential of can-
nabis-based herbal preparations in the various 
diseases and in particular on the treatment of 
pain (research promotion). As part of research 
activities, universities and medical-scientific 
societies can promote pre-clinical, clinical, ob-
servational and epidemiological studies on the 
appropriate use of cannabis-based medicinal 
products, carried out according to the current 
legislation on clinical trials, through the resour-
ces of the Italian Drug Agency, referred to the 
Article 48, paragraphs 18 and 19, letter b), num-
ber 3). Magistral preparations based on FM2 
cannabis can be prescribed by any qualified 
doctor registered in the Order of Physicians, by 
non-repeatable prescription, where the reim-
and reimbursement, monitoring of prescriptions, 
indications, dosage and method of administration, 
methods of decoction preparation, pharmaco-
dynamics and pharmacokinetic properties, con-
traindications, side effects, special warnings and 
precautions for use, interactions with other medi-
cinal products and other forms of interaction, the 
creation of phytosurveillance system for safety 
monitoring. The circular reiterates that “canna-
bis cannot be considered a proper therapy, but a 
symptomatic treatment to support the standard 
ones, when these latter ones have not produced 
the desired effects or have caused non-tolerable 
secondary effects or require dosage increases that 
could determine the appearance of side effects “.
Law Proposal S.2947 “Provisions 
Concerning the Cultivation and 
Administration of Medical Cannabis
During 2017 in Italy the use of cannabis for the-
rapeutic purposes was at the center of the politi-
cal and social debate. In particular, on 30 October 
2017 the Senate approved the Law Decree S.2947 
“Provisions concerning the cultivation and admi-
nistration of medical cannabis” 32.
 The law of the article 1 regulates the use 
of medicinal products of cannabis vegetable 
origin. 2) It guarantees uniform criteria on the 
national territory to access these products. 3) 
It promotes scientific research on possible fur-
ther uses of medical cannabis. 4) It supports the 
development of cannabis production and pro-
cessing techniques, to simplify the methods of 
administration cannabis-based medicines. The 
article 2 explains that ‘medical use’ means the 
administration of cannabis-based medicines 
prescribed after a suitable patient assessment 
and diagnosis, to provide appropriate treat-
ment. The doctor may prescribe magistral pre-
parations based on cannabis for the treatment 
of pain, in agreement to the law of 15 March 
2010, n. 38, at the charge of the National Heal-
th Service. In the prescription, the doctor has 
to indicate the alphanumeric code assigned to 
the patient, the prescribed dose, the dosage and 
the methods of consumption. The prescription 
should also report the date of issue, the duration 
of the individual treatment, which in any case 
cannot exceed three months, as well as the si-
gnature and the stamp of the doctor who issued 
it (Article 3). The regions and the autonomous 
Provinces of Trento and Bolzano annually pro-
vide the data on prescriptions of medical canna-
bis, aggregated by disease and by patients age 
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bursement is established by each Region and 
Autonomous Provinces of Trento and Bolzano.
The Use of Cannabis for Therapeutic 
Purposes is Widespread at European 
Level
European legislation is inconsistent on the use, 
cultivation and possession of cannabis. The three 
United Nations conventions on drugs - to which 
the EU adheres - authorize the use of psychotro-
pic drugs only for medical or scientific purposes. 
The 1988 Convention considers “detention for 
personal use” as a crime. The signatory countries 
are then asked to adhere to international legisla-
tion on the possession of drugs, but it remains 
de facto free on the local policies to be adopted. 
From here it comes the variety of systems con-
ceived in the EU. Cannabis is illegal in France, 
Italy, Poland, Bulgaria, Cyprus, Denmark, Cro-
atia, Finland, Great Britain, Luxembourg, Mal-
ta, Romania, Sweden, Austria, Latvia, Slovakia, 
Slovenia, Lithuania, Belgium, Hungary. It is legal 
in the Netherlands. It is decriminalized in: Ger-
many, Portugal, United Kingdom, Czech Repu-
blic, Spain, Estonia.
Conclusions
Since the last thirty years, cannabis has been 
the most studied plant in the field of medicine 
for its therapeutic properties in a wide range of 
medical conditions, including chronic neuropa-
thic pain management. Central neuropathic pain 
is a medical challenge, due to its serious impact 
on the lives of patients and the difficulties in its 
management. For this reason, cannabinoids may 
represent an extra opportunity in the therapeutic 
luggage of the doctor. Therefore, further studies 
are needed to better define the therapeutic role of 
cannabis and its preparations. Indeed, the results 
on the medical effectiveness of cannabis are still 
controversial and the medical community conti-
nues to be not in agreement with the possibility to 
appeal at this type of treatment. However, given 
that the costs of cannabis for therapeutic use will 
be supported by the National Health Service, it is 
essential both to avoid unrealistic expectations in 
patients and to conduct further studies to make 
the best possible use of public money.
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